Your browser doesn't support javascript.
loading
Cancer-Causative Mutations Occurring in Early Embryogenesis.
Pareja, Fresia; Ptashkin, Ryan N; Brown, David N; Derakhshan, Fatemeh; Selenica, Pier; da Silva, Edaise M; Gazzo, Andrea M; Da Cruz Paula, Arnaud; Breen, Kelsey; Shen, Ronglai; Marra, Antonio; Zehir, Ahmet; Benayed, Ryma; Berger, Michael F; Ceyhan-Birsoy, Ozge; Jairam, Sowmya; Sheehan, Margaret; Patel, Utsav; Kemel, Yelena; Casanova-Murphy, Jacklyn; Schwartz, Christopher J; Vahdatinia, Mahsa; Comen, Elizabeth; Borsu, Laetitia; Pei, Xin; Riaz, Nadeem; Abramson, David H; Weigelt, Britta; Walsh, Michael F; Hadjantonakis, Anna-Katerina; Ladanyi, Marc; Offit, Kenneth; Stadler, Zsofia K; Robson, Mark E; Reis-Filho, Jorge S; Mandelker, Diana.
Afiliação
  • Pareja F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ptashkin RN; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Brown DN; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Derakhshan F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Selenica P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • da Silva EM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gazzo AM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Da Cruz Paula A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Breen K; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Shen R; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Marra A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Zehir A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Benayed R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Berger MF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ceyhan-Birsoy O; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jairam S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Sheehan M; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Patel U; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kemel Y; Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Casanova-Murphy J; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schwartz CJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Vahdatinia M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Comen E; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Borsu L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Pei X; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Riaz N; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Abramson DH; Department of Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Walsh MF; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hadjantonakis AK; Department of Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ladanyi M; Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Offit K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Stadler ZK; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Robson ME; Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Reis-Filho JS; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mandelker D; Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Discov ; 12(4): 949-957, 2022 04 01.
Article em En | MEDLINE | ID: mdl-34949653
ABSTRACT
Mosaic mutations in normal tissues can occur early in embryogenesis and be associated with hereditary cancer syndromes when affecting cancer susceptibility genes (CSG). Their contribution to apparently sporadic cancers is currently unknown. Analysis of paired tumor/blood sequencing data of 35,310 patients with cancer revealed 36 pathogenic mosaic variants affecting CSGs, most of which were not detected by prior clinical genetic testing. These CSG mosaic variants were consistently detected at varying variant allelic fractions in microdissected normal tissues (n = 48) from distinct embryonic lineages in all individuals tested, indicating their early embryonic origin, likely prior to gastrulation, and likely asymmetrical propagation. Tumor-specific biallelic inactivation of the CSG affected by a mosaic variant was observed in 91.7% (33/36) of cases, and tumors displayed the hallmark pathologic and/or genomic features of inactivation of the respective CSGs, establishing a causal link between CSG mosaic variants arising in early embryogenesis and the development of apparently sporadic cancers.

SIGNIFICANCE:

Here, we demonstrate that mosaic variants in CSGs arising in early embryogenesis contribute to the oncogenesis of seemingly sporadic cancers. These variants can be systematically detected through the analysis of tumor/normal sequencing data, and their detection may affect therapeutic decisions as well as prophylactic measures for patients and their offspring. See related commentary by Liggett and Sankaran, p. 889. This article is highlighted in the In This Issue feature, p. 873.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article